Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Mirova in connection with the acquisition of the Boarp, Dållebo and Fågelås wind farms
Mandate

Vinge advises Mirova in connection with the acquisition of the Boarp, Dållebo and Fågelås wind farms

February 10, 2026 M&A

Vinge has advised Mirova, a subsidiary of Natixis Investment Managers focusing on sustainable investments, in connection with the acquisition of the three Swedish onshore wind farms Boarp, Dållebo and Fågelås.

On December 23, 2025, Mirova agreed and completed the acquisition of the three Swedish onshore wind farms Fågelås, Dållebo and Boarp from Eolus AB. Mirova has acquired 100 per cent ownership of the three wind farms, which are equipped with the latest Vestas turbines and a recently signed 15-year power purchase agreement (“PPA”) covering a significant portion of the facilities’ annual electricity production.

Vinge’s team primarily consisted of Christoffer Thalin, Tilda Hall, Agnes Tell, Emma Sääf, Isabelle Ivarsson, Jesper Ottergren, Johan Cederblad, Jonatan Karlsson, Markus Hedbys, Nicolas Ek, Sofie Nordgren and Jasmine Elgh.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026